Received Aug 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | IM / LA |
Pain injection site; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 70-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Concurrent medical conditions included coronary artery disease, blood cholesterol increased and hypertension. Concomitant products included atorvastatin calcium (Lipitor) and losartan potassium (Losartan). On 20-AUG-2025, the patient received the 2nd dose of Shingrix (intramuscular, left arm) .5 ml. On 20-AUG-2025, less than a day after receiving Shingrix, the patient experienced injection site pain (Verbatim: Pain injection site). The outcome of the injection site pain was resolving. It was unknown if the reporter considered the injection site pain to be related to Shingrix. It was unknown if the company considered the injection site pain to be related to Shingrix. Additional Information: GSK Receipt Date: 21-AUG-2025 The reporter is the patient who stated he had arm pain at the injection site right after receiving his second dose of Shingrix and that the pain is still present but is improving. Patient has distended aorta. This case is linked with case US2025107416, reported by the same reporter.; Sender's Comments: US-GSK-US2025107416:same reporter
Blood cholesterol increased; Coronary artery disease; Hypertension
LIPITOR; LOSARTAN